Seminal Cell-Free DNA Assessment as a Novel Prostate Cancer Biomarker


PONTI G., MACCAFERRI M., MANDRIOLI M., MANFREDINI M., MICALI S., COTUGNO M., ...Daha Fazla

PATHOLOGY & ONCOLOGY RESEARCH, cilt.24, sa.4, ss.941-945, 2018 (SCI-Expanded) identifier identifier identifier

  • Yayın Türü: Makale / Tam Makale
  • Cilt numarası: 24 Sayı: 4
  • Basım Tarihi: 2018
  • Doi Numarası: 10.1007/s12253-018-0416-6
  • Dergi Adı: PATHOLOGY & ONCOLOGY RESEARCH
  • Derginin Tarandığı İndeksler: Science Citation Index Expanded (SCI-EXPANDED), Scopus
  • Sayfa Sayıları: ss.941-945
  • Anahtar Kelimeler: Seminal plasma cfDNA, Spermal cfDNA, Prostate cancer, Urological biomarkers, Fluorimetry, Prostate cancer screening, Liquid biopsy, ORIGIN, PLASMA
  • Akdeniz Üniversitesi Adresli: Evet

Özet

Cell-free DNA (cfDNA) includes circulating DNA fragments, which can be obtained from different human biological samples. cfDNA originates either from apoptotic and/or necrotic cells or is actively secreted by cancer cells. As yet, a quantification and size distribution assessment of seminal plasma cfDNA from prostate cancer patients has never been assessed. To discover a novel, sensitive, non-invasive biomarker of prostate cancer, through the fluorometric quantification and the electrophoretic analysis of seminal cfDNA in prostate cancer patients compared to healthy individuals. The concentration of seminal plasma cfDNA in prostate cancer patients was 2243.67 +/- 1758ng/l, compared to 57.7 +/- 4.8ng/l in healthy individuals (p<0.05). Electrophoresis sites distribution patterns were different; ladder fragmentation was associated with prostate cancer patients and apoptotic electrophoretic fragmentation with healthy individuals. Human seminal fluid can be a valuable source of cfDNA in the setting of liquid biopsy procedures for the identification of novel oncological biomarkers. Seminal plasma cfDNA in prostate cancer patients is significantly more concentrated than that of age-matched, healthy controls. Fluorometric measurement and electrophoretic assessment allow a reliable quantification and characterization of seminal plasma cfDNA, which can be used routinely in prostate cancer screening programs.